Oppenheimer reissued their hold rating on shares of Intellia Therapeutics (NASDAQ:NTLA) in a research report released on Tuesday morning.

Several other equities analysts also recently issued reports on the stock. ValuEngine downgraded shares of Intellia Therapeutics from a hold rating to a sell rating in a report on Wednesday, November 15th. Barclays reaffirmed a buy rating on shares of Intellia Therapeutics in a report on Sunday, November 5th. Credit Suisse Group increased their price objective on shares of Intellia Therapeutics from $24.00 to $28.00 and gave the company an outperform rating in a report on Friday, November 3rd. Jefferies Group set a $42.00 price objective on shares of Intellia Therapeutics and gave the company a buy rating in a report on Tuesday, October 31st. Finally, Leerink Swann increased their price objective on shares of Intellia Therapeutics from $29.00 to $37.00 and gave the company an outperform rating in a report on Tuesday, October 31st. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of Hold and an average target price of $30.17.

Intellia Therapeutics (NTLA) traded down $0.84 on Tuesday, reaching $18.30. 985,300 shares of the company’s stock traded hands, compared to its average volume of 352,928. Intellia Therapeutics has a fifty-two week low of $10.83 and a fifty-two week high of $33.34.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Tuesday, October 31st. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.06. The business had revenue of $7.30 million for the quarter, compared to the consensus estimate of $5.83 million. Intellia Therapeutics had a negative net margin of 215.92% and a negative return on equity of 28.01%. The company’s revenue was up 49.0% compared to the same quarter last year. During the same period last year, the firm posted ($0.22) earnings per share. equities research analysts predict that Intellia Therapeutics will post -1.68 EPS for the current year.

In other news, CEO Nessan Bermingham sold 336,783 shares of the firm’s stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $20.78, for a total value of $6,998,350.74. Following the transaction, the chief executive officer now directly owns 696,000 shares of the company’s stock, valued at $14,462,880. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 12.80% of the company’s stock.

Several large investors have recently bought and sold shares of NTLA. Vanguard Group Inc. lifted its stake in shares of Intellia Therapeutics by 3.9% in the first quarter. Vanguard Group Inc. now owns 904,708 shares of the company’s stock worth $12,747,000 after buying an additional 33,925 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Intellia Therapeutics by 6.0% in the first quarter. Geode Capital Management LLC now owns 76,095 shares of the company’s stock worth $1,072,000 after buying an additional 4,291 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its stake in shares of Intellia Therapeutics by 6.1% in the first quarter. Schwab Charles Investment Management Inc. now owns 26,903 shares of the company’s stock worth $380,000 after buying an additional 1,539 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of Intellia Therapeutics by 443.6% in the first quarter. Bank of America Corp DE now owns 17,840 shares of the company’s stock worth $251,000 after buying an additional 14,558 shares in the last quarter. Finally, Bank of Montreal Can lifted its stake in shares of Intellia Therapeutics by 1,031.7% in the second quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock worth $127,000 after buying an additional 7,222 shares in the last quarter. 49.55% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.watchlistnews.com/intellia-therapeutics-ntla-given-hold-rating-at-oppenheimer/1761573.html.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.